论文部分内容阅读
目的为麦特美在临床的正确应用提供依据。方法以我院2004年以来住院的糖尿病患者64例为观察对象,采用自身前后对照法进行临床疗效观察。统计学处理计量资料以x±s表示,组间比较采取t检验。结果对服用磺酰脲类降糖药未能使血糖满意控制的非胰岛素依靠型糖尿病患者,加麦特美联合治疗后明显降低空腹和餐后2 h血糖水平,其中疗效差10例,占总病例的15%,失败的原因可能与饮食失控、应激、情绪不稳定和麦特美失效有关。麦特美的主要不良反应为腹泻和恶心,一般在服药1周后逐渐消失。结论麦特美是临床应用最广泛的双胍类降糖药,有良好的降糖效果,极少引起乳酸性酸中毒。
The purpose is to provide the basis for the correct clinical application. Methods Sixty-four inpatients with diabetes mellitus since 2004 in our hospital were observed, and their clinical efficacy was observed by self-control method. Statistical analysis of measurement data to x ± s, said the comparison between groups t test. Results After taking sulfonylurea hypoglycemic agents that could not make blood glucose satisfactory, non-insulin-dependent diabetes mellitus patients treated with combination of gammetrexed significantly reduced fasting and 2-hour postprandial blood glucose levels, of which 10 cases had poor efficacy Fifteen percent of the cases, the cause of failure may be related to uncontrolled diet, stress, emotional instability and Mattel failure. Mettler’s main adverse reactions are diarrhea and nausea, which generally disappear after 1 week of treatment. Conclusion Mettermesilide is the most widely used biguanide hypoglycemic agent in clinical practice. It has good hypoglycemic effect and rarely causes lactic acidosis.